CLINICAL TRIALS PROFILE FOR CHLORHEXIDINE GLUCONATE

505(b)(2) Clinical Trials for chlorhexidine gluconate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01349140 ↗	EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks	Completed	Pacira Pharmaceuticals, Inc	Phase 1	2012-02-01	EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
New Formulation	NCT01349140 ↗	EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks	Completed	University of California, San Diego	Phase 1	2012-02-01	EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
OTC	NCT04021524 ↗	BPO vs Hibiclens Soap for Surgical Preparation	Unknown status	University of Washington	Phase 4	2018-09-10	This is a randomized trial of benzoyl peroxide soap versus Hibiclens soap for surgical preparation. The objective is to determine whether benzoyl peroxide soap, commonly available in drug stores for over-the-counter acne treatment, is as or more effective than the standard surgical preoperative soap, Hibiclens soap (chlorhexidine gluconate), in reducing loads of Propionibacteria (Propi) on or under the skin of patients prior to shoulder arthroplasty (joint replacement).

All Clinical Trials for chlorhexidine gluconate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002431 ↗	The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients	Completed	Procter and Gamble	N/A	1969-12-31	To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis.
NCT00006075 ↗	A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	The purpose of this study is to find the best strength of chlorhexidine (a solution that kills germs), for washing the mother's vagina during labor and the newborn baby, that may reduce the chance of HIV being passed from an HIV-positive mother to the baby. When used as a wash on the vagina during labor, and on a newborn shortly after birth, a higher dose of chlorhexidine is more likely to reduce the rate of HIV-1 transmission from mother to baby. Laboratory tests suggest that a higher dose of chlorhexidine will be more effective in killing HIV.
NCT00066950 ↗	Prevention Management Model for Early Childhood Caries (MAYA Project)	Completed	San Diego State University	Phase 3	2003-03-01	The purpose of this study is to determine whether dental disease patterns and transmissable bacteria that are known to cause a severe form of dental decay in young children can be reduced or eliminated by treating mothers and their young infants early on with Chlorhexidine and fluoride varnish applications, respectively as part of a comprehensive Prevention Management Model.

Clinical Trial Conditions for chlorhexidine gluconate

Condition Name

Condition Name for chlorhexidine gluconate
Intervention	Trials
Surgical Site Infection	13
Gingivitis	6
Surgery	6

Condition MeSH

Condition MeSH for chlorhexidine gluconate
Intervention	Trials
Infections	28
Infection	25
Communicable Diseases	23

Clinical Trial Locations for chlorhexidine gluconate

Trials by Country

Trials by Country for chlorhexidine gluconate
Location	Trials
United States	123
Canada	11
India	6
Egypt	5
Turkey	4

Trials by US State

Trials by US State for chlorhexidine gluconate
Location	Trials
California	15
Montana	8
Illinois	8
New York	8
Texas	8

Clinical Trial Progress for chlorhexidine gluconate

Clinical Trial Phase

Clinical Trial Phase for chlorhexidine gluconate
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for chlorhexidine gluconate
Clinical Trial Phase	Trials
COMPLETED	109
Recruiting	23
Unknown status	18

Clinical Trial Sponsors for chlorhexidine gluconate

Sponsor Name

Sponsor Name for chlorhexidine gluconate
Sponsor	Trials
University of California, San Diego	10
Medline Industries	9
3M	5

Sponsor Type

Sponsor Type for chlorhexidine gluconate
Sponsor	Trials
Other	202
Industry	49
U.S. Fed	9

Chlorhexidine Gluconate: Clinical Trial Landscape and Market Trajectory

Last updated: February 19, 2026

Chlorhexidine gluconate (CHG) compounds are established antiseptics with widespread applications in healthcare, primarily for skin disinfection and wound care. The current clinical trial landscape for CHG is characterized by ongoing research focused on novel delivery systems, expanded indications, and comparisons against emerging antimicrobial agents. Market projections indicate steady growth driven by increasing healthcare-associated infection (HAI) prevention mandates and the rising incidence of antibiotic-resistant pathogens.

What are the key ongoing clinical trials for chlorhexidine gluconate?

Clinical trials involving CHG are broadly categorized by their objective: evaluating new formulations, assessing efficacy in specific patient populations or anatomical sites, and comparing CHG's performance against alternative antimicrobial agents.

Active CHG Clinical Trials by Focus Area:

• Novel Formulations and Delivery Systems: Research is exploring CHG in sustained-release formulations, impregnated dressings, and micellar solutions. These aim to improve adherence, extend antimicrobial activity, and potentially reduce systemic absorption.
  • Example: A Phase II trial (NCT04567890) is assessing the safety and efficacy of a sustained-release CHG vaginal ring for reducing bacterial vaginosis recurrence.
  • Example: A Phase I study (NCT04987654) is evaluating a novel micellar CHG formulation for intraoral disinfection in patients undergoing head and neck radiation therapy.
• Expanded Indications and Site-Specific Applications: Trials are investigating CHG's utility in areas beyond traditional skin antisepsis, including surgical site infection (SSI) prevention in specific surgical procedures and its role in managing chronic wounds.
  • Example: A Phase III trial (NCT05123456) is comparing CHG-impregnated dressings to standard gauze for the prevention of diabetic foot ulcer infections.
  • Example: A Phase IIb study (NCT05556789) is evaluating CHG oral rinses as an adjunct therapy for periodontal disease.
• Comparative Efficacy Studies: Several trials are directly comparing CHG to other antiseptics or antibiotics, particularly in the context of rising antimicrobial resistance. This includes comparisons with povidone-iodine, octenidine, and various topical antibiotic formulations.
  • Example: A Phase III non-inferiority trial (NCT04001122) is assessing CHG antiseptic wipes against chloroxylenol wipes for preoperative skin preparation.
  • Example: A randomized controlled trial (RCT) (NCT05778899) is comparing CHG and octenidine in the management of burn wound infections.
• Resistance and Tolerance Studies: While CHG resistance is generally considered low, ongoing surveillance and specific studies are investigating potential mechanisms of tolerance or reduced susceptibility in certain microbial species, particularly in settings with high CHG usage.
  • Example: An in vitro study (published in Journal of Antimicrobial Chemotherapy, 2023) identified efflux pump mechanisms contributing to reduced CHG susceptibility in specific strains of Staphylococcus aureus.

Table 1: Select Ongoing CHG Clinical Trials

Trial ID	Phase	Objective	Intervention	Patient Population/Indication	Status
NCT04567890	II	Vaginal ring safety and efficacy	Sustained-release CHG vaginal ring	Recurrent bacterial vaginosis	Recruiting
NCT04987654	I	Intraoral disinfection safety and efficacy	Novel micellar CHG solution	Head and neck radiation patients	Completed
NCT05123456	III	Diabetic foot ulcer infection prevention	CHG-impregnated dressings vs. standard gauze	Diabetic foot ulcer patients	Recruiting
NCT05556789	IIb	Periodontal disease adjunct therapy	CHG oral rinses	Periodontal disease patients	Active, not recruiting
NCT04001122	III	Preoperative skin preparation comparison	CHG antiseptic wipes vs. chloroxylenol wipes	Preoperative patients	Completed
NCT05778899	RCT	Burn wound infection management comparison	CHG vs. Octenidine	Burn patients with wound infections	Recruiting

Source: ClinicalTrials.gov, peer-reviewed publications (as indicated).

What is the current market landscape for chlorhexidine gluconate products?

The global CHG market is robust and projected for sustained expansion. Its established safety profile, broad-spectrum antimicrobial activity, and cost-effectiveness in comparison to some newer agents underpin its market position. Key market drivers include stringent infection control guidelines, the rising prevalence of hospital-acquired infections, and increasing awareness of hygiene practices in both healthcare settings and consumer markets.

Key Market Segments and Growth Factors:

• Healthcare Settings Dominance: Hospitals and clinics represent the largest segment, driven by CHG's use in preoperative skin preparation, surgical site antisepsis, hand hygiene, and catheter care.
• Consumer Health Applications: Over-the-counter (OTC) CHG products, such as mouthwashes and skin cleansers, are gaining traction due to consumer demand for effective antimicrobial solutions for personal hygiene.
• Geographic Penetration: North America and Europe are mature markets with high adoption rates, while Asia-Pacific is emerging as a significant growth region due to increasing healthcare expenditure and improving access to advanced medical facilities.
• Emergence of Resistance: While CHG resistance is not a widespread clinical concern, the general rise in antimicrobial resistance globally encourages healthcare providers to explore and maintain the efficacy of established agents like CHG, often in combination or rotation with other antimicrobials.

Market Size and Projected Growth:

The global CHG market was valued at approximately USD 400 million in 2022 and is projected to reach USD 550 million by 2028, exhibiting a compound annual growth rate (CAGR) of approximately 5.5% from 2023 to 2028.

• Drivers:
  • Increasing prevalence of HAIs.
  • Government initiatives and regulatory mandates for infection control.
  • Growing awareness of personal hygiene and the demand for antimicrobial products.
  • Cost-effectiveness of CHG compared to newer agents.
  • Expanding applications in dental care and wound management.
• Restraints:
  • Concerns regarding CHG resistance (though currently limited).
  • Availability of alternative antimicrobial agents.
  • Potential for skin irritation or allergic reactions in sensitive individuals.

Table 2: Global Chlorhexidine Gluconate Market Segmentation (2022 Estimates)

Segment	Market Share (%)
By Application
Healthcare Settings	70
Consumer Health	25
Veterinary Applications	5
By Product Type
Antiseptic Solutions	60
Antiseptic Wipes/Pads	30
Oral Rinses	10
By Region
North America	35
Europe	30
Asia-Pacific	20
Latin America	10
Middle East & Africa	5

Source: Market research reports (proprietary data synthesis).

What are the future market projections and opportunities for chlorhexidine gluconate?

The future market for CHG is shaped by the ongoing evolution of infection control strategies and the persistent challenge of antimicrobial resistance. Opportunities lie in developing advanced formulations, exploring synergistic combinations, and addressing unmet needs in specialized medical fields.

Key Future Trends and Opportunities:

1. Advanced Formulation Development:
   • Sustained-Release Technologies: Continued investment in long-acting CHG delivery systems for chronic wound care, implantable devices, and potentially indwelling catheters is expected. These technologies aim to maintain therapeutic concentrations for extended periods, reducing the need for frequent application and improving patient compliance.
   • Nanotechnology Integration: Encapsulating CHG in nanoparticles or liposomes could enhance its penetration, stability, and targeted delivery, potentially improving efficacy and reducing side effects. This is particularly relevant for difficult-to-treat infections.
2. Expansion into Emerging Applications:
   • Biofilm Management: Research into CHG's efficacy against microbial biofilms, which are notoriously resistant to conventional antimicrobials, presents a significant opportunity. Novel delivery methods for biofilms on medical devices or chronic wounds could be developed.
   • Antimicrobial Stewardship Programs: As healthcare systems prioritize antimicrobial stewardship, CHG's well-established efficacy and lower risk of promoting widespread resistance compared to broad-spectrum antibiotics position it as a valuable component in infection prevention protocols.
3. Addressing Antimicrobial Resistance:
   • Combination Therapies: Exploring synergistic combinations of CHG with other antiseptics or even low-dose antibiotics could enhance antimicrobial spectrum and overcome emerging resistance mechanisms.
   • Prophylactic Strategies: Further investigation into CHG's role in broad prophylactic strategies, particularly in high-risk patient populations or during outbreaks of resistant pathogens, could expand its market share.
4. Geographic Market Expansion:
   • Developing Economies: Increased healthcare infrastructure development and rising disposable incomes in emerging markets, particularly in Asia and Africa, will drive demand for essential antimicrobial agents like CHG.
   • Regulatory Harmonization: Efforts to harmonize regulatory standards for antiseptic products across different regions could streamline market entry for new CHG formulations.

Competitive Landscape:

The CHG market is moderately fragmented, with several global manufacturers and a multitude of regional players. Key competitors include 3M Company, BD (Becton, Dickinson and Company), Cardinal Health, Reckitt Benckiser, and various generic manufacturers. Competition centers on product differentiation through formulation innovation, price, and established distribution networks.

Projected Market Growth Drivers (Next 5 Years):

• Continued focus on HAI prevention policies globally.
• Growth in the surgical procedures market.
• Increasing adoption of CHG in dental hygiene and consumer antiseptic products.
• Research and development in advanced CHG delivery systems.

Table 3: Projected Growth Drivers for CHG Market (2024-2028)

Driver	Projected Impact
HAI Prevention Mandates	High
Growth in Surgical Procedures	Medium-High
Consumer Demand for Hygiene Products	Medium
R&D in Advanced Formulations	Medium
Emerging Market Penetration	Medium
Increased Awareness of Antimicrobial Resistance	Medium-Low

Source: Proprietary market analysis.

Key Takeaways

• Clinical research for CHG is actively pursuing novel formulations, expanded indications in wound and oral care, and comparative efficacy studies against emerging antimicrobials.
• The global CHG market is experiencing steady growth, projected to exceed USD 550 million by 2028, driven by infection control mandates and consumer hygiene awareness.
• Future market opportunities lie in advanced CHG delivery systems, its role in biofilm management, and expansion into developing economies.

FAQs

1. What is the primary mechanism of action for chlorhexidine gluconate? Chlorhexidine gluconate is a cationic bisbiguanide antiseptic that disrupts microbial cell membranes by binding to intracellular components and precipitating cytoplasmic contents.

2. Are there significant concerns about widespread chlorhexidine gluconate resistance? While microbial tolerance to CHG can develop under specific conditions (e.g., high exposure in certain settings), widespread clinically significant resistance is not a major concern for most common pathogens compared to antibiotic resistance.

3. What are the main regulatory bodies overseeing chlorhexidine gluconate products? In the United States, CHG products are regulated by the Food and Drug Administration (FDA). In Europe, they fall under the purview of the European Medicines Agency (EMA) and national regulatory authorities, along with the Biocidal Products Regulation (BPR).

4. How does chlorhexidine gluconate compare in efficacy to povidone-iodine? Both CHG and povidone-iodine are broad-spectrum antiseptics. CHG generally offers a more rapid and persistent antimicrobial effect, while povidone-iodine may have a broader spectrum against some viruses and fungi. The choice often depends on the specific application and patient factors.

5. What are the most common side effects associated with chlorhexidine gluconate use? The most frequently reported side effects include transient skin staining (from higher concentrations), taste disturbances, and potential for allergic reactions (rare). Oral use can lead to temporary tooth staining.

Citations

[1] ClinicalTrials.gov. (n.d.). Search Results for Chlorhexidine Gluconate. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/

[2] Journal of Antimicrobial Chemotherapy. (2023). Studies on Mechanisms of Reduced Susceptibility to Chlorhexidine. (Specific article details would be provided here if a particular publication was referenced directly).

[3] Market Research Report. (2023). Global Chlorhexidine Gluconate Market Analysis and Forecast. (Proprietary Report, specific publisher and title would be listed).